Multiple Sclerosis | Treatment Algorithms: Claims Data Analysis | US | 2025

The treatment landscape for multiple sclerosis (MS) in the U.S. is rapidly evolving, with over 20 immunomodulatory disease-modifying therapies (DMTs) available and more in development. The market reflects the disease’s heterogeneity, personalized treatment approaches, and the distinct clinical profiles of each DMT. As new therapies launch and generics increase competition, the space grows more crowded. Meanwhile, early use of high-efficacy drugs is replacing traditional escalation strategies. For companies entering or operating in this market, understanding where their products—especially next-in-class options—fit is critical. Our Treatment Algorithms study analyses national patient-level claims data to track therapy progression by line of therapy, brand-level persistence and compliance, and current DMT positioning.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MS patients?
• How have anti-CD20 monoclonal antibodies been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of MS patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• How have the availability of generic oral DMTs influenced treatment decisions and prescribing behavior?
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Markets covered: United States

Key companies: Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mylan / Viatris, Novartis, Sanofi, Teva, TG Therapeutics

Key drugs: Aubagio / teriflunomide, Bafiertam, Briumvi, Copaxone / glatiramer acetate, Gilenya / fingolimod, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ocrevus Zunovo, Ponvory, Tecfidera / dimethyl fumarate, Tysabri, Vumerity, Zeposia

Key analysis provided

• Brand / therapy usage across patient sample.
• Newly diagnosed patient analysis.
• Treatment initiation and progression.
• Line of therapy analysis.
• Source of business for recently treated patients.
• Persistency and compliance analysis.
• Product-level patient flow.

Key feature

• Dashboard featuring interactive visuals, easy navigation, and expanded analyses.